Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice
- PMID: 39843919
- PMCID: PMC11894078
- DOI: 10.1038/s41431-025-01785-1
Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice
Abstract
The popularity of multi-gene testing has identified more families with two or more pathogenic variants (PV) in cancer predisposition genes, also known as 'MINAS' (multilocus inherited neoplasia alleles syndromes). They are at risk of suboptimal treatment and management as little on this topic is known. We conducted a systematic review of published MINAS cases within cancer predisposition genes to understand their association with more severe presentations. We analysed 413 MINAS carriers, which included 33 novel cases from the Cancer Genetics Service, National Cancer Centre Singapore. Statistical tests were conducted to assess association between carrier characteristics and the number PV identified. Results suggest that MINAS carriers have more malignancies (31.7% vs 21.5% vs 10.3% %; p < 0.001), a younger median age of first cancer diagnosis (40.0 vs. 44.0 vs. 49.0 years; p < 0.001) and an early onset of cancer (defined as <5% PV-associated cancer risk at age of diagnosis) (24.9% vs 7.7% vs 4.7%; p < 0.001) compared to monoallelic and non-carriers. We also studied the association of clinical characteristics by the dominant or recessive nature of PV harboured, where more dominant-dominant (D-D) carriers reported multiple malignancies (34.0%), compared to dominant-recessive (D-R) (23.9%) and recessive-recessive (R-R) carriers (20%;) (p = 0.051). Our findings suggest that MINAS carriers are prone to more and younger malignancies and the dominant or recessive nature of PV within double carriers can affect clinical presentation. We suggest a framework to guide management based on the dominant or recessive nature of PV within double PV carriers.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The authors declare no competing interest. Ethics approval: This study is approved by SingHealth Centralized Institutional Review Board (CIRB 2018/2456). Written informed consent was obtained for publication of genetic and clinical data of novel local cases included in this article.
Figures
Similar articles
-
Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database.Breast Cancer. 2025 Jul;32(4):792-802. doi: 10.1007/s12282-025-01704-8. Epub 2025 May 5. Breast Cancer. 2025. PMID: 40323562 Free PMC article.
-
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x. Respir Res. 2024. PMID: 39709425 Free PMC article. Review.
-
The ultimate power play in research - partnering with patients, partnering with power.Res Involv Engagem. 2025 Jun 17;11(1):65. doi: 10.1186/s40900-025-00745-9. Res Involv Engagem. 2025. PMID: 40528262 Free PMC article.
-
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887. Elife. 2025. PMID: 40407808 Free PMC article.
-
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.Cochrane Database Syst Rev. 2023 Sep 12;9(9):CD015226. doi: 10.1002/14651858.CD015226.pub2. Cochrane Database Syst Rev. 2023. PMID: 37696529 Free PMC article.
Cited by
-
Spring in EJHG.Eur J Hum Genet. 2025 Mar;33(3):259-260. doi: 10.1038/s41431-025-01828-7. Eur J Hum Genet. 2025. PMID: 40065122 No abstract available.
References
-
- Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143–53. - PubMed
-
- Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2020;18:380–91. - PubMed
-
- Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1:943–51. - PubMed
-
- Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Breast Cancer Res Treat. 2017;166:315–9. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical